



**IMPORTANT INSULIN INFORMATION**  
**DISCONTINUATION OF Velosulin® BR Human (Buffered Regular Human Insulin Injection [rDNA origin])**

November 2003

Dear Healthcare Professional,

We wish to inform you that **Novo Nordisk Pharmaceuticals, Inc., will be discontinuing Velosulin® BR Human (Buffered Regular Human Insulin Injection [rDNA origin]).**

Under the current order and consumption levels, we estimate that retail pharmacies will deplete their supplies of Velosulin BR by approximately April 30, 2004.

The following treatment options should be considered:

- NovoLog® (insulin aspart [rDNA origin] injection) is the only other insulin product that is FDA approved for subcutaneous insulin infusion via an external insulin pump. It is an insulin analog that is indicated for the treatment of adult patients with diabetes mellitus, for the control of hyperglycemia. NovoLog is available by prescription only.
- For questions regarding the replacement of Velosulin BR with other insulin products, please contact the manufacturer for appropriate instructions.

Any change in insulin therapy should be made cautiously and under medical supervision.

If you require further information, please contact the Novo Nordisk Customer Support Center at **1-800-727-6500**, Monday through Friday between the hours of 8:00 a.m. and 7:00 p.m. EST.

Sincerely,

Campbell P. Howard, M.D.  
Clinical Director, Medical Affairs

Velosulin and NovoLog are registered trademarks of Novo Nordisk A/S

**Novo Nordisk  
Pharmaceuticals Inc.**

100 College Road  
West  
Princeton, NJ, 08540  
USA

Telephone:  
609-987-5800

Internet:  
<http://www.novonordisk-us.com/>